MET and non-small cell lung carcinoma: The VISION study of tepotinib exhibited an ORR of 56% (95% CI 45–66%) in patients with locally advanced or metastatic NSCLC and MET exon 14 skipping mutation, regardless of previously treated or untreated NSCLC investigator assessed [13].